Search Results

BioSkryb Genomics announced a partnership with Research Instruments Pte Ltd, a premier distributor for genomic and life science research products in Southeast Asia, to distribute BioSkryb’s ResolveDNA® and ResolveOME™ single cell amplification tools throughout Singapore and Southeast Asia.

ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems, and Radiant Digital PTE Ltd. a provider of digital transformation delivery services to commercial and government clients, have partnered to facilitate the digital transformation of life sciences companies in Singapore.

SCG Cell Therapy Pte Ltd announced that U.S. Food and Drug Administration has approved the Investigational New Drug application to initiate Phase 1/2 clinical trial for SCG142, a novel next-generation human papillomavirus E7-specific T-cell receptor-engineered T cell therapy for patients with HPV-associated solid tumors.

PharmaGend Global Medical Services Pte. Ltd., jointly invested by China Medical System Holdings Limited, through its wholly-owned subsidiary CMS MEDICAL VENTURE PTE. LTD., and its non-wholly owned subsidiary Rxilient Health Pte. Ltd., with Pharmaron International Limited and Healthy Goal Limited, has entered into a lease agreement for the building and property located in Tuas, Singapore and completed the purchase of certain production machines and equipment from Strides Pharma Global Pte.

OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of Unyvero systems to Camtech Pte Ltd (“Camtech”), a Singaporean family office for $218,000.

Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that it has entered into a distribution agreement with BIOASIA PTE LTD (“Bioasia”), a medical diagnostics distributor located in Singapore.

Helsinn Group and Juniper Biologics Pte Ltd announced the signing of an exclusive distribution license and supply agreement to register, distribute, promote, market and sell LEDAGA® in Australia, Asia and the Middle East* as a topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma in adults.

SCG Cell Therapy Pte Ltd, a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, announced that clinical data from its first-in-class autologous hepatitis B virus -specific T-cell receptor-engineered T Cell therapy – SCG101 – was featured in a late-breaking session during the European Association for the Study of the Liver Congress 2024 in Milan, Italy.